Back to Search Start Over

Protective non-neutralizing SARS-CoV-2 monoclonal antibodies.

Authors :
Izadi A
Nordenfelt P
Source :
Trends in immunology [Trends Immunol] 2024 Aug; Vol. 45 (8), pp. 609-624. Date of Electronic Publication: 2024 Jul 20.
Publication Year :
2024

Abstract

Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be answered regarding the characteristics of protective non-neutralizing mAbs, including the models and assays used for study, the risks of ensuing detrimental inflammation, as well as the durability and mechanisms of protection.<br />Competing Interests: Declaration of interests A.I. and P.N. have a patent pending for anti-SARS-CoV-2 mAbs.<br /> (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Details

Language :
English
ISSN :
1471-4981
Volume :
45
Issue :
8
Database :
MEDLINE
Journal :
Trends in immunology
Publication Type :
Academic Journal
Accession number :
39034185
Full Text :
https://doi.org/10.1016/j.it.2024.06.003